Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacrosidase for Fructan Intolerance
NCT05703009Phase 2Completed
- Sponsor
- QOL Medical
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacrosidase in fructan intolerance (2 arms), sponsored by QOL Medical. Primary endpoint: Total Symptom Score at 1 week. Started Jun 2023; status: completed.
02
Drugs
sacrosidase
03
Conditions
fructan intolerance
Beyond the preview
Go deeper on NCT05703009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703009.